ERVACCINE TECHNOLOGIES
Ervaccine Technologies a developer of next-generation cancer vaccines that targets endogenous retroviruses.
ERVACCINE TECHNOLOGIES
Industry:
Biotechnology Pharmaceutical
Founded:
2019-01-10
Address:
Lyon, Rhone-Alpes, France
Country:
France
Total Employee:
1+
Status:
Active
Total Funding:
2.5 M EUR
Similar Organizations
Alchemab Therapeutics
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Current Employees Featured
Founder
Investors List
Seventure Partners
Seventure Partners investment in Seed Round - Ervaccine Technologies
More informations about "Ervaccine Technologies"
Ervaccine Technologies - VentureRadar
ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies based on the identification of new families of tumor antigens. We are …See details»
home - ErVimmune
Mar 19, 2025 To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. …See details»
Ervaccine Technologies - Funding, Financials, Valuation & Investors
Ervaccine Technologies is a biotechnology company that develops cancer vaccines and T cell-based immunotherapies. New. Resources. Advanced Search. Start Free Trial . Talk With …See details»
ErVaccine raises €4.5M to start therapeutic cancer vaccine trial
ErVimmune 2025 Company Profile: Valuation, Funding & Investors …
Ervaccine Technologies. Ownership Status. Privately Held (backing) Financing Status. Venture Capital-Backed. Corporate Office. Centre Léon Berard; 28 Rue Laennec; ... Technology (CPC) …See details»
ErVaccine Technologies - CRCL
ErVaccine Technologies, spin off du Centre Léon Bérard (CLB)/Centre de Recherche en Cancérologie de Lyon (CRCL), a été fondée en octobre 2019 par le Pr. Stéphane Depil, onco-hématologue au CLB, sur la base des travaux de …See details»
ErVimmune closes a €4.5 million financing round and …
Jan 5, 2023 About ErVaccine Technologies ErVaccine Technologies is a preclinical stage biotechnology company, founded in October 2019 by Prof. Stéphane Depil, an onco-haematologist and researcher at the Centre Léon …See details»
Seed Round - Ervaccine Technologies - 2023-01-05 - Crunchbase
Jan 5, 2023 Organization Name . Ervaccine Technologies . Announced Date Jan 5, 2023; Funding Type Seed; Funding Stage Seed; Money Raised . obfuscated. obfuscated. ...See details»
Startup ERVACCINE TECHNOLOGIES Vaccins anticancéreux de …
Vaccins anticancéreux de nouvelle génération. La biotech Ervaccine Technologies concentre ses recherches sur la composante virale du microbiote et son impact sur le système immunitaire, …See details»
ErVaccinces Technologies raises €4.5M and announces first ... - CRCL
Jan 12, 2023 The biotec company ErVaccine Technologies, spin-off of the Centre Léon Bérard and the CRCL, which develops next-generation therapeutic vaccines and cellular …See details»
ErVaccine Technologies : des vaccins thérapeutiques contre le cancer
Mar 24, 2023 Délégation Rhône Auvergne Identité, missions et organisation; Recherche Laboratoires et sciences pour tous; Innovation Les partenariats et les acteurs de la recherche; …See details»
ErVaccine - Overview, News & Similar companies | ZoomInfo.com
ErVaccine Technologies develops breakthrough immunotherapies combining cancer vaccines and T-cell therapies to address a high medical need in cold tumors. We are dedicated to …See details»
CNRS Innovation » ErVaccine Technologies : des vaccins …
ErVaccine Technologies : des vaccins thérapeutiques contre le cancer. Publié le 22 mars 2023 | par Thierry Lucas. La start-up, qui a bouclé un financement de 4,5 millions d'euros, développe …See details»
ErVimmune Announces Inaugural Members of Scientific Advisory …
Feb 23, 2023 Download the press release. Lyon, France – February 23, 2023 – ErVaccine Technologies, a French biotech company developing next-generation therapeutic vaccines …See details»
Ervaccine Technologies - Crunchbase
Ervaccine Technologies is a biotechnology company that develops cancer vaccines and T cell-based immunotherapies. New. Resources. Advanced Search. ... Experience the new …See details»
ErVimmune - Products, Competitors, Financials, Employees, …
Organisation > ErVaccine is developing a therapeutic vaccine and cell therapy technology potentially applicable to many types of cancers > First vaccine candidate planned to start …See details»
FDA approves Bavarian Nordic’s freeze-dried mpox and smallpox …
3 days ago The World Health Organization (WHO) has said the mpox outbreak is still a public health emergency, as per a February update. There have been more than 100,000 cases …See details»
Pfizer’s RSV vaccine wins expanded approval in EU, gaining edge …
3 days ago The approval represents another step forward for Pfizer in the RSV vaccine market, where it competes with GSK’s Arexvy. While GSK has secured approval for older adults, it has …See details»
Revolutionizing immunization: a comprehensive review of mRNA …
Mar 12, 2025 Messenger RNA (mRNA) vaccines have emerged as a transformative platform in modern vaccinology. mRNA vaccine is a powerful alternative to traditional vaccines due to …See details»
ErVimmune Announces Renewing Bioinformatics Team to support …
Jun 15, 2023 Download the presse release. Lyon, France – June 15, 2023 – ErVaccine Technologies, a French biotechnology company developing next-generation therapeutic …See details»